title: Bevacizumab (Avastin) as a surgical adjunct in diabetic vitrectomy for fibrovascular disease.
authors.forename: J S
authors.initials: JS
authors.lastname: Gandhi
authors.forename: L T
authors.initials: LT
authors.lastname: Tan
authors.forename: I
authors.initials: I
authors.lastname: Pearce
authors.forename: S J
authors.initials: SJ
authors.lastname: Charles
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D006801:Humans; D012167:Retinal Perforations / Q000139:chemically induced*; D014821:Vitrectomy
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab